Inovio Pharmaceuticals Inc. (INO)

2.45
0.07 2.78
NASDAQ : Health Technology
Prev Close 2.52
Open 2.48
Day Low/High 2.41 / 2.50
52 Wk Low/High 1.92 / 5.50
Volume 808.73K
Avg Volume 611.50K
Exchange NASDAQ
Shares Outstanding 99.03M
Market Cap 255.00M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Adding to 2 Positions

We'll purchase more shares of Pixelworks and Inovio ahead of their quarterly results next week.

Stocks Under $10 Weekly Summary

We made several trades and price target changes during a mixed week for the portfolio.

Raising Our Price Target on 2 Holdings, Cutting It on One

Sometimes, changing the price target is better than selling (or buying).

Stocks Under $10 Weekly Summary

The portfolio has some high fliers and underperformers last week as we head into the heart of earnings season.

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

Identifying this week's bullish and bearish reversal patterns.

September 15th Options Now Available For Inovio Pharmaceuticals (INO)

September 15th Options Now Available For Inovio Pharmaceuticals (INO)

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading today, for the September 15th expiration.

Oversold Conditions For Inovio Pharmaceuticals (INO)

Oversold Conditions For Inovio Pharmaceuticals (INO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Biotech Movers: Sarepta, Inovio, Mylan

Biotech Movers: Sarepta, Inovio, Mylan

Sarepta Therapeutics, Inovio Pharmaceuticals and Mylan were among the biotech movers in premarket trading on July 20.

Adding to a Name on Weakness

It's hard to ignore INO's price this far below our cost basis.

Biotech Movers: Vertex Continues to Move on Data for CF Regimen

Biotech Movers: Vertex Continues to Move on Data for CF Regimen

Vertex Pharmaceuticals, FibroGen and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading trading on July 19.

A Pharma Pairs Trade

We'll take some profits in AcelRx and lower our cost basis on Inovio.

Stocks Under $10 Weekly Summary

We brought a new name into the portfolio last week as the Fed's comments helped lift the market.

Adding to a Biotech Position

We'll lower our cost basis on Inovio Pharmaceuticals.

Stocks Under $10 Weekly Summary

We made no trades during the holiday-shortened week, but added to our natural hedge today.

Biotech Movers: Exelixis, Omeros, Inovio

Biotech Movers: Exelixis, Omeros, Inovio

Exelixis, Omeros and Inovio Pharmaceuticals were among the biotech movers in premarket trading on July 10.

Inovio's DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation

Inovio's DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation

Inovio dMAb® product induces complete protection against lethal challenge with influenza A & B viruses in published preclinical study

Stocks Under $10 Weekly Summary

We added a name to the portfolio's Bullpen as a whirlwind quarter came to an end.

Inovio Announces Leadership Appointments

Stocks Under $10 Weekly Summary

We exited 2 positions and took some profits during a busy week for the portfolio.

Stocks Under $10 Weekly Summary

We initiated a new position and made several other trades during a week of twists and turns.

Stocks Under $10 Weekly Summary

We initiated 2 new positions in a week dominated by political events.

Adding to Inovio Pharmaceuticals

INO has reached our bid levels.

Initiating Position in Biotech; Update on ACRX

We're buying a small position in Inovio Pharmaceuticals and downgrading AcelRx.

Inovio Pharmaceuticals: Cramer's Top Takeaways

Inovio Pharmaceuticals: Cramer's Top Takeaways

Jim Cramer takes a closer look at Inovio Pharmaceuticals, a small biotech developing DNA-based immunotherapies to treat cancer.

Stay Focused, People!: Cramer's 'Mad Money' Recap (Thursday, 6/8/17)

Stay Focused, People!: Cramer's 'Mad Money' Recap (Thursday, 6/8/17)

Jim Cramer says the story is less about Comey vs. Trump than it is about Nvidia vs. Nordstrom.

TheStreet Quant Rating: D- (Sell)